Evidence map›Paper›PMID 41309999›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trial.

Martin Manley, Guilherme Nader-Marta, Ayça Arcay Ozturk, Mutaz Kassas, Francoise Rothé, Loubna Taraji, Christos Sotiriou, Zena Wimana, Roberto Salgado, Patrick Flamen and 1 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Martin Manley *Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles, Brussels, Belgium.
Guilherme Nader-Marta *Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Ayça Arcay OzturkDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles, Brussels, Belgium.
Mutaz KassasDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles, Brussels, Belgium.
Francoise RothéBreast Cancer Translational Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Loubna TarajiDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles, Brussels, Belgium.
Christos SotiriouMedical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Zena WimanaDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles, Brussels, Belgium.
Roberto SalgadoDepartment of Pathology, ZAS Hospitals, Antwerp, Belgium.
Patrick FlamenDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles, Brussels, Belgium.
Géraldine GebhartDepartment of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles, Brussels, Belgium. geraldine.gebhart@hubruxelles.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) improves survival in metastatic castration-resistant prostate cancer. PSMA is also expressed in triple-negative breast cancer (TNBC), a subtype with limited treatment options. This prospective study assessed PSMA uptake on [

methodsThis single-center prospective study enrolled patients with progressive mTNBC. Each patient underwent [

resultsTwenty patients (median age 53.5 years; median 3 prior systemic therapies) were included. On visual assessment, 50.0% had PSMA uptake exceeding liver in most lesions. Quantitative analysis included 106 FDG-avid TLs; 67.0% showed PSMA SUVmax above liver. On a per-patient basis, 35.0% had all TLs and 30.0% had most TLs above liver SUVmean. However, 65.0% had at least one lesion below liver background, indicating heterogeneity. Higher PSMA uptake was associated with fewer prior treatments, prior immunotherapy, and low androgen receptor expression. PSMA PET/CT identified brain metastases in 10.0% of patients.

conclusion[

Indexed as

Antigens, SurfaceEdetic AcidGlutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyTriple Negative Breast NeoplasmsAdultAgedFemaleGallium IsotopesGallium RadioisotopesHumansMiddle AgedNeoplasm MetastasisProspective StudiesAntigens, SurfaceEdetic AcidFOLH1 protein, humangallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIFDG PET/CTPSMA PET/CTTriple-negative breast cancer

Identifiers

PMID41309999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.